Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohortJennifer Murphy, Meredith Pasmantier Kim, Pam Factor‐Litvak et al.|Neurology|2016Cited by 81
Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of AgeDaniel González, Michael Cohen‐Wolkowiez, Debra L. Palazzi et al.|The Pediatric Infectious Disease Journal|2017Cited by 44
Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of AgeDaniel González, Michael Cohen‐Wolkowiez, John S. Bradley et al.|Open Forum Infectious Diseases|2016Cited by 6